ClinicalTrials.gg
CompletedNCT01453205Updated Mar 12, 2018Results posted

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 interventional study of MEDI-551 2 mg/kg and Rituximab in Diffuse Large B-Cell Lymphoma, sponsored by MedImmune LLC. Completed at 83 sites in 11 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-03-12.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · AstraZeneca.

Enrollment
3rd of 11
187 · median 67
Started
2012
the only one that year
Phase 2
3 of 12
1 open now
Registered
1st of 12
by date

Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, or all of them as a file.
02

Study summary

The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, B-Cell Malignancy, anti-CD19, monoclonal antibody, second line, ASCT, Refractory
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed aggressive B-cell DLBCL, including FL transforming to DLBCL \& Grade III FL
  • from or refractory to at least one treatment containing rituximab or another anti-CD20 based immunotherapy combined with anthracycline- or anthracenedione-based chemotherapy
  • Eligible for
  • (ECOG) performance status of 0, 1, or 2
  • of ≥ 12 weeks
  • Adequate hematological function

Exclusion criteria

Exclusion Criteria:

  • Any chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for treatment of lymphoma within 28 days prior to treatment
  • Previous cancer therapy for DLBCL other than anthracycline- or anthracenedione based chemoimmunotherapy, monotherapy rituximab prior to therapy and/or as a maintenance therapy, or limited field radiotherapy
  • Prior or allogeneic SCT
  • ≥ Class II congestive heart failure; abnormality on
  • History of other invasive within 5 years except for localized/in situ, carcinomas such as cervical carcinoma in situ.
  • Evidence of active infection
  • Documented current central nervous system involvement by leukemia or lymphoma
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Active comparator
    Rituximab+ ICE/DHAP

    Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m\^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.

    Drug: Rituximab · Drug: ICE · Drug: DHAP · Procedure: Autologous Stem Cell Transplant (ASCT)

  • Experimental
    MEDI-551 2 mg/kg + ICE/DHAP

    Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.

    Drug: MEDI-551 2 mg/kg · Drug: ICE · Drug: DHAP · Procedure: Autologous Stem Cell Transplant (ASCT)

  • Experimental
    MEDI-551 4 mg/kg + ICE/DHAP

    Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.

    Drug: ICE · Drug: DHAP · Procedure: Autologous Stem Cell Transplant (ASCT) · Drug: MEDI-551 4 mg/kg

Interventions

  • DrugMEDI-551 2 mg/kg

    Drug page: Inebilizumab

    MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).

    Also known as: Inebilizumab

  • Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).

    Also known as: Rituxan; MabThera

  • DrugICE

    ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.

  • DrugDHAP

    Drug pages: Dexamethasone · Cytarabine · Cisplatin

    DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.

  • ProcedureAutologous Stem Cell Transplant (ASCT)

    Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.

  • DrugMEDI-551 4 mg/kg

    Drug page: Inebilizumab

    MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).

    Also known as: Inebilizumab

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate is defined as the proportion of participants with a best response of complete response (CR) or partial response (PR) according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50 percent (%) decrease in the sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant nodal masses and greater than or equal to (\>=) 50% decrease in SPD of spleen/liver nodules.

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from randomization until the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. PFS (months) = (Date of PD/death or censoring - Date of randomization + 1) / (365.25/12).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  2. Event-Free Survival (EFS)

    Event-Free Survival (EFS) is defined as the time from randomization until the first documentation of EFS events which include PD, initiation of alternative antitumor treatment or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. EFS (months) = (Date of EFS or censoring - Date of randomization + 1) / (365.25/12).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  3. Overall Survival (OS)

    Overall survival is defined as the time from randomization until death due to any cause according to the International Working Group criteria. OS (months) = (Date of death or censoring - Date of randomization + 1) / (365.25/12).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  4. Time to Progression (TTP)

    Time to Progression (TTP) is defined as the time from randomization until the first documentation of PD according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. TTP (months) = (Date of PD or censoring - Date of randomization + 1) / (365.25/12).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  5. Time to Response (TTR)

    Time to response (TTR) is defined as the time from randomization until the first documentation of disease response according to the International Working Group criteria. Only participants who have achieved objective response (confirmed CR or confirmed PR) assessed by investigator were evaluated for TTR. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. TTR (months) = (Date of first disease response - Date of randomization + 1) / (365.25/12).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  6. Duration of Response (DR)

    Duration of Response (DR) is defined as time from start of first documented objective response (confirmed CR or confirmed PR) to first documented PD according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \> 50% increase from nadir in the SPD of any previous lesions. Only participants who have achieved objective response assessed by investigator were evaluated. DR calculated as (months) = (Date of PD or censoring - Date of first disease response + 1)/ (365.25/12).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  7. Number of Participants With Best Overall Response Assessed by Blinded Independent Central Review (BICR)

    The best overall response was calculated, based upon the disease assessments recorded during the study visits, and summarized with the number of participants for the following categories: CR, PR, stable disease (SD), PD, and unknown. Responses were assessed according to the International Working Group criteria. CR: disappearance of all evidence of disease; PR: 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules; PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions; SD: failure to attain CR/PR or PD.

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  8. Acceptable Dose of MEDI-551

    Acceptable dose for MEDI-551 was evaluated based on the benefit-risk analysis.

    Time frame: After the administration of the first dose of MEDI-551 (7 days before the Cycle 1) to last dose of MEDI-551 (Cycle 3 Day 1) (each cycle of 21 days)

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An Adverse Event (AE) is any unfavourable and unintended signs, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. Serious adverse event (SAE) is any AE that resulted in death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, life-threatening, a congenital anomaly/birth defect, or an important medical event. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug, up to 90 days after the end of treatment (EOT).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Hematology/Coagulation Laboratory Results

    An abnormal laboratory finding that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment (EOT).

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  11. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Chemistry Laboratory Results (Include Urinalysis)

    An abnormal laboratory findings that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  12. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs and ECG Abnormalities

    Vital signs included parameters such as heart rate, blood pressure, temperature, and respiratory rate. An abnormal vital signs and ECG findings that was judged by the investigator to be clinically significant was reported an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.

    Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)

  13. Number of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA)

    A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study.

    Time frame: 7 days before the start of Cycle 1, Day 1 of each subsequent Cycle, EOT, and post EOT on Days 30, 60, 90 and 270 (up to 36 months from the randomization of last participant)

  14. Mean Serum Concentration of MEDI-551

    The mean serum concentration of MEDI-551 were observed.

    Time frame: Cycle 1 Day -7 Post dose, pre-dose and postdose on Day 1, post-dose on Days 4, 8, 15 of Cycle 1, pre-dose and postdose on Day 1 of Cycle 2 and Cycle 3

  15. Half-life (T1/2) of MEDI-551

    Terminal elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.

    Time frame: Cycle 1 and EOT (Day 21 of Cycle 3 [each cycle of 21 days] or earlier cycles if treatment stopped before Cycle 3)

07

Results

Posted Mar 12, 2018

Participant flow

The study was conducted from 27Feb2012 to 17Jun2016.

Participant flow — Overall Study
MilestoneRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Started805255
Completed001
Not completed805254
Withdrew: Lost to follow-up301
Withdrew: Withdrawal by subject830
Withdrew: Death242218
Withdrew: Other452735

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective Response Rate is defined as the proportion of participants with a best response of complete response (CR) or partial response (PR) according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50 percent (%) decrease in the sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant nodal masses and greater than or equal to (\>=) 50% decrease in SPD of spleen/liver nodules.

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Objective Response Rate (ORR)47.5 (36.2 to 59.0)46.2 (32.2 to 60.5)43.6 (30.3 to 57.7)
Statistical analysis
  • Rituximab+ ICE/DHAP vs MEDI-551 4 mg/kg + ICE/DHAP · Cochran-Mantel-Haenszel · p = 0.5543
SecondaryProgression-Free Survival (PFS)

Progression-free survival (PFS) is defined as the time from randomization until the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. PFS (months) = (Date of PD/death or censoring - Date of randomization + 1) / (365.25/12).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Progression-Free Survival (PFS)6.1 (0.0 to 39.2)6.6 (0.0 to 31.3)7.7 (0 to 14.8)
Statistical analysis
  • Rituximab+ ICE/DHAP vs MEDI-551 4 mg/kg + ICE/DHAP · Log Rank · p = 0.8567
SecondaryEvent-Free Survival (EFS)

Event-Free Survival (EFS) is defined as the time from randomization until the first documentation of EFS events which include PD, initiation of alternative antitumor treatment or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. EFS (months) = (Date of EFS or censoring - Date of randomization + 1) / (365.25/12).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Median · months
Event-Free Survival (EFS)
monthsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Event-Free Survival (EFS)4.7 (0.0 to 39.2)4.2 (0.0 to 31.3)5.9 (0.0 to 14.8)
Statistical analysis
  • Rituximab+ ICE/DHAP vs MEDI-551 4 mg/kg + ICE/DHAP · Log Rank · p = 0.7412
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization until death due to any cause according to the International Working Group criteria. OS (months) = (Date of death or censoring - Date of randomization + 1) / (365.25/12).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Median · months
Overall Survival (OS)
monthsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Overall Survival (OS)NA (15.6 to NA)NA (14.2 to NA)23.0 (12.8 to NA)
Statistical analysis
  • Rituximab+ ICE/DHAP vs MEDI-551 4 mg/kg + ICE/DHAP · Log Rank · p = 0.9996
SecondaryTime to Progression (TTP)

Time to Progression (TTP) is defined as the time from randomization until the first documentation of PD according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. TTP (months) = (Date of PD or censoring - Date of randomization + 1) / (365.25/12).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Median · months
Time to Progression (TTP)
monthsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Time to Progression (TTP)4.9 (0.0 to 11.1)4.2 (0.0 to 31.3)5.9 (0.0 to 14.0)
Statistical analysis
  • Rituximab+ ICE/DHAP vs MEDI-551 4 mg/kg + ICE/DHAP · Log Rank · p = 0.1686
SecondaryTime to Response (TTR)

Time to response (TTR) is defined as the time from randomization until the first documentation of disease response according to the International Working Group criteria. Only participants who have achieved objective response (confirmed CR or confirmed PR) assessed by investigator were evaluated for TTR. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. TTR (months) = (Date of first disease response - Date of randomization + 1) / (365.25/12).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Median · months
Time to Response (TTR)
monthsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Time to Response (TTR)1.7 (0.9 to 3.8)2.3 (1.5 to 3.4)2.3 (1.6 to 6.0)
SecondaryDuration of Response (DR)

Duration of Response (DR) is defined as time from start of first documented objective response (confirmed CR or confirmed PR) to first documented PD according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \> 50% increase from nadir in the SPD of any previous lesions. Only participants who have achieved objective response assessed by investigator were evaluated. DR calculated as (months) = (Date of PD or censoring - Date of first disease response + 1)/ (365.25/12).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Median · months
Duration of Response (DR)
monthsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Duration of Response (DR)NA (4.9 to NA)7.1 (4.1 to NA)7.9 (4.6 to 12.2)
SecondaryNumber of Participants With Best Overall Response Assessed by Blinded Independent Central Review (BICR)

The best overall response was calculated, based upon the disease assessments recorded during the study visits, and summarized with the number of participants for the following categories: CR, PR, stable disease (SD), PD, and unknown. Responses were assessed according to the International Working Group criteria. CR: disappearance of all evidence of disease; PR: 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules; PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions; SD: failure to attain CR/PR or PD.

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response Assessed by Blinded Independent Central Review (BICR)
ParticipantsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
COMPLETE RESPONSE (CR)20 (16.0 to 35.9)6 (4.4 to 23.4)12 (11.8 to 35.0)
PARTIAL RESPONSE (PR)181812
STABLE DISEASE (SD)171214
PROGRESSIVE DISEASE (PD)555
UNKNOWN201112
SecondaryAcceptable Dose of MEDI-551

Acceptable dose for MEDI-551 was evaluated based on the benefit-risk analysis.

Time frame:
After the administration of the first dose of MEDI-551 (7 days before the Cycle 1) to last dose of MEDI-551 (Cycle 3 Day 1) (each cycle of 21 days)
Reported as:
Number · milligram per kilogram (mg/kg)
Acceptable Dose of MEDI-551
milligram per kilogram (mg/kg)MEDI-551
Acceptable Dose of MEDI-5514
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An Adverse Event (AE) is any unfavourable and unintended signs, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. Serious adverse event (SAE) is any AE that resulted in death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, life-threatening, a congenital anomaly/birth defect, or an important medical event. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug, up to 90 days after the end of treatment (EOT).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
TEAEs785152
TESAEs332527
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Hematology/Coagulation Laboratory Results

An abnormal laboratory finding that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment (EOT).

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Hematology/Coagulation Laboratory Results
ParticipantsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Anaemia473233
Febrile neutropenia16912
Granulocytopenia302
Leukopenia9610
Lymphopenia423
Neutropenia301520
Pancytopenia203
Thromobocytopenia492429
Activated partial thromboplastin time prolonged020
Blood immunoglobulin g decreased010
Blood immunoglobulin m decreased010
Haemoglobin decreased010
Immunoglobulins decreased010
Lymphocyte count decreased943
Neutrophil count decreased768
Platelet count decreased12810
Platelet count increased010
White blood cell count decreased656
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Chemistry Laboratory Results (Include Urinalysis)

An abnormal laboratory findings that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Chemistry Laboratory Results (Include Urinalysis)
ParticipantsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Hyperbilirubinaemia100
Hypernatraemia311
Hyperphosphataemia002
Hypertriglyerideaemia100
Hyperuricaemia541
Hypoalbuminaemia343
Hypocalcaemia1167
Hypoglycaemia111
Hypokalaemia241314
Hypomagnesaemia17611
Hyponatraemia822
Hypophosphataemia433
Hypoproteinaemia001
Alanine aminotransferase increased724
Aspartate aminotransferase increased526
Blood alkaline phosphatase increased201
Blood bicarbonate decreased100
Blood bilirubin increased111
Blood chloride increased010
Blood creatinine increased1057
Blood lactate dehydrogenase increased211
Blood magnesium decreased200
Blood potassium decreased200
Blood uric acid decreased010
Blood uric acid increased110
Gamma-glutamyltransferase increased933
Hepatic enzyme increased101
Protein total decreased011
Transaminases increased120
Dysuria213
Hematuria230
Glucose urine present011
Proteinuria011
Urine sodium increased001
Calcium deficiency001
Electrolyte imbalance200
Hypercalcaemia210
Hyperglycaemia1292
Hyperkalaemia221
Hypermagnesaemia320
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs and ECG Abnormalities

Vital signs included parameters such as heart rate, blood pressure, temperature, and respiratory rate. An abnormal vital signs and ECG findings that was judged by the investigator to be clinically significant was reported an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.

Time frame:
From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs and ECG Abnormalities
ParticipantsRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Arrhythmia002
Atrial fibrillation112
Bradycardia312
Extrasystoles010
Palpitations210
Sinus arrhythmia001
Sinus bradycardia121
Systolic dysfunction001
Tachycardia312
Pyrexia171411
Blood pressure increased001
Carbon dioxide decreased100
Electrocardiogram abnormal001
Electrocardiogram QT prolonged022
Heart rate irregular100
Weight decreased011
Weight increased101
Dyspnoea1178
Dyspnoea exertional031
Hypertension523
Hypotension1048
SecondaryNumber of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA)

A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study.

Time frame:
7 days before the start of Cycle 1, Day 1 of each subsequent Cycle, EOT, and post EOT on Days 30, 60, 90 and 270 (up to 36 months from the randomization of last participant)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA)
ParticipantsMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Number of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA)10
SecondaryMean Serum Concentration of MEDI-551

The mean serum concentration of MEDI-551 were observed.

Time frame:
Cycle 1 Day -7 Post dose, pre-dose and postdose on Day 1, post-dose on Days 4, 8, 15 of Cycle 1, pre-dose and postdose on Day 1 of Cycle 2 and Cycle 3
Reported as:
Mean · mcg/mL
Mean Serum Concentration of MEDI-551
mcg/mLMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Cycle 1 Day-7 Post Dose47.0 ± 23.783.8 ± 21.9
Cycle 1 Day 1 Pre Dose16.7 ± 5.8133.1 ± 16.3
Cycle 1 Day 1 Post Dose64.8 ± 26.4116 ± 41.3
Cycle 1 Day 438.8 ± 14.671.9 ± 23.0
Cycle 1 Day 830.6 ± 9.6969.3 ± 25.1
Cycle 1 Day 1519.4 ± 6.1944.7 ± 25.0
Cycle 2 Day 1 Pre Dose15.0 ± 5.4530.9 ± 14.3
Cycle 2 Day 1 Post Dose52.3 ± 18.7112 ± 32.6
Cycle 3 Day 1 Pre Dose14.0 ± 6.5036.4 ± 18.7
Cycle 3 Day 1 Post Dose52.4 ± 16.9116 ± 30.9
SecondaryHalf-life (T1/2) of MEDI-551

Terminal elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.

Time frame:
Cycle 1 and EOT (Day 21 of Cycle 3 [each cycle of 21 days] or earlier cycles if treatment stopped before Cycle 3)
Reported as:
Mean · Day
Half-life (T1/2) of MEDI-551
DayMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Cycle 114.4 ± 5.0916.5 ± 10.5
End of Treatment18.9 ± 4.3420.2 ± 5.73

Adverse events

Collected over From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab+ ICE/DHAP—33/79 (41.8%)78/79 (98.7%)
MEDI-551 2 mg/kg + ICE/DHAP—25/52 (48.1%)49/52 (94.2%)
MEDI-551 4 mg/kg + ICE/DHAP—27/54 (50%)52/54 (96.3%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
Febrile neutropeniaBlood and lymphatic system disorders11/798/529/54
SepsisInfections and infestations3/791/524/54
ThrombocytopeniaBlood and lymphatic system disorders5/790/521/54
Acute kidney injuryRenal and urinary disorders3/793/522/54
NeutropeniaBlood and lymphatic system disorders4/791/523/54
PyrexiaGeneral disorders1/792/522/54
Tumour lysis syndromeMetabolism and nutrition disorders0/792/521/54
SyncopeNervous system disorders0/792/520/54
Pleural effusionRespiratory, thoracic and mediastinal disorders0/792/522/54
PneumoniaInfections and infestations3/790/521/54
Most frequent other events
Showing 10 of 104
Most frequent other events
EventRituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAP
AnaemiaBlood and lymphatic system disorders47/7932/5233/54
ThrombocytopeniaBlood and lymphatic system disorders47/7924/5228/54
NauseaGastrointestinal disorders43/7923/5225/54
FatigueGeneral disorders22/7920/5215/54
NeutropeniaBlood and lymphatic system disorders27/7915/5218/54
ConstipationGastrointestinal disorders23/7917/5218/54
VomitingGastrointestinal disorders26/7914/5214/54
HypokalaemiaMetabolism and nutrition disorders24/7913/5214/54
DiarrhoeaGastrointestinal disorders19/7915/5213/54
AstheniaGeneral disorders9/7912/5211/54

Baseline characteristics

Intent-To-Treat population included all participants who were randomized into the study.

Age, Continuous
Age, Continuous(YEARS)Rituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAPTOTAL
Mean56.4 ± 12.356.9 ± 11.455.9 ± 11.656.4 ± 11.8
Age, Customized
Age, Customized(Participants)Rituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAPTOTAL
< 65 YEARS603543138
>= 65 YEARS20171249
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab+ ICE/DHAPMEDI-551 2 mg/kg + ICE/DHAPMEDI-551 4 mg/kg + ICE/DHAPTOTAL
Female35192478
Male453331109
08

Study locations

83 sites
  • Research Site
    Birmingham, Alabama 35061, United States
  • Research Site
    Burbank, California 91501, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Sylmar, California 91342, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Hazard, Kentucky 41701, United States
  • Research Site
    Lafayette, Louisiana 70503, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Baltimore, Maryland 21215, United States
  • Research Site
    Minneapolis, Minnesota 55455, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Kansas City, Missouri 66160, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Bronx, New York 10466, United States
  • Research Site
    Fargo, North Dakota 58102, United States
  • Research Site
    Dayton, Ohio 45403, United States
  • Research Site
    Newark, Ohio 43055, United States
  • Research Site
    Sylvania, Ohio 43560, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Lubbock, Texas 79410, United States
  • Research Site
    Morgantown, West Virginia 26505, United States
  • Research Site
    Milwaukee, Wisconsin 53266, United States
  • Research Site
    St. John, New Brunswick E2E5A2, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Brno, 12808, Czechia
  • Research Site
    Praha 2, 12808, Czechia
  • Research Site
    Praha, 12808, Czechia
  • Research Site
    Bordeaux, 33300, France
  • Research Site
    Le Mans, 72000, France
  • Research Site
    Libourne Cedex, 33205, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Marseille, 13273, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Rouen, 76100, France
  • Research Site
    Tours, 37100, France
  • Research Site
    Berlin, 10967, Germany
  • Research Site
    Frankfurt, 65929, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Muenchen, 80804, Germany
  • Research Site
    Tuebingen, 72076, Germany
  • Research Site
    Wuerzburg, 97080, Germany
  • Research Site
    Budapest, 01083, Hungary
  • Research Site
    Debrecen, 04032, Hungary
  • Research Site
    Gyor, 09200, Hungary
  • Research Site
    Kaposvar, 07400, Hungary
  • Research Site
    Ashkelon, 78278, Israel
  • Research Site
    Haifa, 31999, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Gdynia, 81-519, Poland
  • Research Site
    Lublin, 20081, Poland
  • Research Site
    Nizhny Novgorod, 603126, Russian Federation
  • Research Site
    Saint Petersburg, 197341, Russian Federation
  • Research Site
    St. Petersburg, 191024, Russian Federation
  • Research Site
    St. Petersburg, 197341, Russian Federation
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Cadiz, 11009, Spain
  • Research Site
    Girona, 17007, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08907, Spain
  • Research Site
    Madrid, 28025, Spain
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Malaga, 29010, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    San Sebastian de los Reyes, 28702, Spain
  • Research Site
    Sevilla, 41013, Spain
  • Research Site
    Sevilla, 41014, Spain
  • Research Site
    Valencia, 46015, Spain
  • Research Site
    Valencia, 46017, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Izmir, 35100, Turkey
  • Research Site
    Izmir, 35340, Turkey
  • Research Site
    Kurupelit, 55139, Turkey
  • Research Site
    Malatya, 44100, Turkey
  • Research Site
    Talas, 38280, Turkey
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Jul 2016, 52 months.

Results were first posted in Mar 2018, 1 year 8 months after primary completion. A results delay was requested in Jun 2017.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 52 months is above that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2011
First posted
Oct 17, 2011
StartActual
Feb 27, 2012
Primary completionActual
Jul 11, 2016
CompletionActual
Jul 11, 2016
Results delay requested
Jun 29, 2017
Results first posted
Mar 12, 2018
Last update
Mar 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01453205
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
Feb 27, 2012
Primary completion
Jul 11, 2016
Completion
Jul 11, 2016
Results posted
Mar 12, 2018
Last update
Mar 12, 2018

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion